Study: NCT03175367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: SC or IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: SC or IV administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Lipid Modifying Therapy (LMT)
Description: All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Lipid Modifying Therapy (LMT)
Description: All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Lipid Modifying Therapy (LMT)
Description: All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Lipid Modifying Therapy (LMT)
Description: All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Lipid Modifying Therapy (LMT)
Description: All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Lipid Modifying Therapy (LMT)
Description: All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Lipid Modifying Therapy (LMT)
Description: All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.